TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications, including incretin therapies, to older adults. It calls for assessment of function, nutrition and cognition, and highlights risks such as muscle loss, frailty and dehydration.
The American Geriatrics Society (AGS) has released a case-based framework to help clinicians prescribe obesity medications to older adults while accounting for age-related risks and individual priorities. Published in the Journal of the American Geriatrics Society, the paper applies the AGS Geriatrics 5Ms to incretin therapies, including GLP-1 medications, and calls for assessment of function, nutrition and cognition before treatment.
The framework was developed by the AGS Healthy Aging Special Interest Group and is organized around clinical cases. It offers a practical approach for considering obesity medication use in older people, a population the authors say is underrepresented in clinical trials. The paper discusses potential benefits of these medications for weight management, glycemic control and other health conditions, while stressing that clinicians must weigh those potential benefits against the needs and vulnerabilities of each patient.
Among the issues the authors identify are sarcopenia and frailty, loss of lean muscle, malnutrition and dehydration. They recommend pretreatment review of a patient’s functional status, nutritional adequacy and cognitive impairment. The framework also places treatment within broader care rather than treating medication as a stand-alone intervention.
The authors recommend pairing medication with measures including resistance training and adequate dietary protein. For some patients, they say, care may be best delivered by a team that includes a registered dietitian, physical therapist, fitness trainer and behavioral health professional. The article is by Elias M. Wisdom and colleagues and is titled “Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.” Its DOI is 10.1111/jgs.70769.
Balancing Weight Treatment With Healthy Aging
The framework addresses a clinical gap: obesity medications may offer benefits, but evidence from trials may not fully reflect the circumstances of older adults. Age-related changes in muscle mass, mobility, nutrition and hydration can affect how treatment is considered and monitored. A focus on those factors may help clinicians discuss potential trade-offs instead of relying on weight change alone.
The paper’s emphasis on the patient’s priorities also matters because treatment goals can differ. Maintaining independence, mobility and adequate nutrition may be central concerns alongside weight management or blood sugar control. The framework provides clinicians with a structure for bringing those considerations into prescribing discussions; it does not establish that a particular medication is appropriate for every older person.
Pairing medication with strength-building activity and nutritional support reflects the authors’ concern about lean muscle loss and other vulnerabilities. The proposed team-based approach could also connect prescribing decisions to practical support, though the paper’s framework does not itself show that these measures improve outcomes or specify a single care model for all patients.
Products Worth Considering
Ring Battery Doorbell 2K Plus (2nd Gen) and Spotlight Cam Plus Battery Bundle
TCL T7 Series 85-Inch 4K 144Hz QLED Smart Google TV
Dyson Car+Boat Cordless Handheld Vacuum
As an affiliate, we earn on qualifying purchases.
The Geriatrics 5Ms in Prescribing
The framework adapts the AGS’s Geriatrics 5Ms: Mind, Mobility, Medications, Multicomplexity and Matters Most. These categories direct attention to cognition, movement and function, the full medication regimen, multiple health conditions, and what the patient values. The paper applies them specifically to incretin therapy and obesity medication decisions in older adults.
Incretin medications act through gut-derived hormonal pathways. The source report describes them as offering promising benefits for weight management, glycemic control and other conditions. However, older adults are underrepresented in clinical trials, leaving clinicians with less direct trial evidence for this group than the framework’s authors say is needed. The paper is guidance for applying geriatric considerations, not a report of a new clinical trial or a change to medication approvals.
“The framework calls for pretreatment assessment of functional status, nutritional adequacy and cognitive impairment.”
— Elias M. Wisdom and colleagues, authors of the AGS framework
Evidence Gaps and Individual Risk
The source report does not provide trial results showing how well the framework works in practice, nor does it quantify medication risks or benefits specifically for older adults. It also does not identify which patients are most likely to benefit or provide medication-by-medication prescribing rules. The authors’ concerns and recommendations should be understood as guidance described in the paper, not proof that a given approach prevents harm.
It remains unclear how widely clinicians will adopt the framework and what resources will be available for team-based care. Decisions about obesity medications are individual medical decisions; patients should discuss their circumstances and treatment options with a qualified health professional.
Applying the Framework in Care
The paper’s next step is its use by clinicians as a structure for conversations and assessments when considering obesity medications for older patients. Those discussions can address function, nutrition, cognition, other medications and the patient’s own goals, alongside possible supportive measures such as resistance training and dietary planning.
The source material does not announce a follow-up study, implementation program or timeline for updated guidance. Further research involving older adults could help clarify benefits, risks and outcomes for this population; no such study or timetable is specified in the report.
Key Questions
What did the American Geriatrics Society publish?
The AGS published a case-based framework for patient-centered prescribing of obesity medications in older adults, applying its Geriatrics 5Ms to incretin therapy.
Which issues should clinicians assess before treatment?
The paper recommends reviewing functional status, nutritional adequacy and cognitive impairment, while considering risks including frailty, sarcopenia, muscle loss and dehydration.
Does the framework recommend medication alone?
No. The authors recommend pairing treatment with resistance training and adequate dietary protein. They say some patients may benefit from team-based support.
Does the paper establish that these medications are safe for all older adults?
No. The framework offers prescribing considerations, not a guarantee of safety or a finding that every older adult should receive these medicines. The report notes that older adults are underrepresented in clinical trials.
Where was the framework published?
It appeared in the Journal of the American Geriatrics Society in 2026. The paper’s DOI is 10.1111/jgs.70769.
Source: medicalxpress.com
